Longeveron Q1 net loss $5.0M; HLHS trial 95% enrolled, BLA on track for 2026

Longeveron Inc.

2025-Q1 EPS reported -$0.34 revenue$381,000

Q1 2025 net loss $5.0M (up 23% YoY) on revenue $0.4M (down 30%); cash $14.3M, funding late into Q3 2025.
HLHS pivotal trial ELPIS II ~95% enrolled, completion Q2 2025; BLA submission for full traditional approval anticipated in 2026.
CLEAR MIND Alzheimer's Phase 2a results published in Nature Medicine; FDA agreed on pivotal Phase 2/3 trial design for BLA.
Company plans to seek additional financing and partnerships for BLA readiness and Alzheimer's program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.